Turning the gene tap off; implications of regulating gene expression for cancer therapeutics

Molecular Cancer Therapeutics

Volumn 7, Issue 3, 2008, Pages 439-448

  Curtin, James F ^b   Candolfi, Marianela ^b   Xiong, Weidong ^b   Lowenstein, Pedro R ^b   Castro, Maria G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

A 6; ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; GENE THERAPY AGENT; GROWTH FACTOR; ICOVIR 5; ICOVIR 5 PLUS EVEROLIMUS; ICOVIR 5 TEMOZOLOMIDE; INTERLEUKIN 1; INTERLEUKIN 13 PSEUDOMONAS EXOTOXIN CONJUGATE; INTERLEUKIN 2; INTERLEUKIN 6; MASPIN; PARVOVIRUS VECTOR; PLASMINOGEN ACTIVATOR INHIBITOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; THYMIDINE KINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; WX 671;

ANGIOGENESIS; APOPTOSIS; CANCER GENE THERAPY; CLINICAL TRIAL; DIZZINESS; DRUG HALF LIFE; EXPRESSION VECTOR; GENE EXPRESSION REGULATION; GENE SWITCHING; GENE TECHNOLOGY; GENETIC ENGINEERING; GLIOBLASTOMA; GYNECOLOGIC CANCER; HUMAN; HYPESTHESIA; IMMUNE SYSTEM; IMMUNOSTIMULATION; KIDNEY CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; ONCOGENE; OROPHARYNX HYPESTHESIA; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SENSORY NEUROPATHY; SUICIDE GENE THERAPY; TRANSCRIPTION REGULATION; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTINEOPLASTIC AGENTS; GENE EXPRESSION REGULATION; HUMANS; NEOPLASMS;

EID: 41649103031     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-2328     Document Type: Review

References (53)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Edelstein ML, Abedi MR, Wixon J, Edelstein RM. Gene therapy clinical trials worldwide 1989-2004 - an overview. J Gene Med 2004;6:597-602.
3. Peng Z. Current status of gendicine in China: recombinant human Adp53 agent for treatment of cancers. Hum Gene Ther 2005;16:1016-27.
4. Garber K. China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst 2006;98:298-300.
5. Fox JL. Gene-therapy death prompts broad civil lawsuit. Nat Biotechnol 2000;18:1136.
6. Bouchie A. US policy may encourage counterfeit drugs. Nat Biotechnol 2003;21:121.
7. Goverdhana S, Puntel M, Xiong W, et al. Regulatable gene expression systems for gene therapy applications: progress and future challenges. Mol Ther 2005;12:189-211.
8. Candolfi M, Curtin JF, Xiong WD, et al. Effective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells. Mol Ther 2006;14:371-81.
9. Xiong W, Goverdhana S, Sciascia SA, et al. Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses. J Virol 2006;80:27-37.
10. Xiong W, Candolfi M, Kroeger KM, et al. Immunization against the transgene but not the TetON switch reduces expression from gutless adenoviral vectors in the brain. Mol Ther 2008;16:343-51.
11. Hillen W, Berens C. Mechanisms underlying expression of Tn10 encoded tetracycline resistance. Annu Rev Microbiol 1994;48:345-69.
12. Gu J, Zhang L, Huang X, et al. A novel single tetracycline-regulative adenoviral vector for tumor-specific Bax gene expression and cell killing in vitro and in vivo. Oncogene 2002;21:4757-64.
13. Williams JC, Stone D, Smith-Arica JR, Morris ID, Lowenstein PR, Castro MG. Regulated, adenovirus-mediated delivery of tyrosine hydroxylase suppresses growth of estrogen-induced pituitary prolactinomas. Mol Ther 2001;4:593-602.
14. Wulff H, Krieger T, Kruger K, et al. Cloning and characterization of an adenoviral vector for highly efficient and doxycycline-suppressible expression of bioactive human single-chain interleukin 12 in colon cancer. BMC Biotechnol 2007;7:35.
15. Hwang JJ, Scuric Z, Anderson WF. Novel retroviral vector transferring a suicide gene and a selectable marker gene with enhanced gene expression by using a tetracycline-responsive expression system. J Virol 1996;70:8138-41.
16. Kamper MR, Gohla G, Schluter G. A novel positive tetracycline-dependent transactivator (rtTA) variant with reduced background activity and enhanced activation potential. FEBS Lett 2002;517:115-20.
17. Lamartina S, Roscilli G, Rinaudo CD, et al. Stringent control of gene expression in vivo by using novel doxycycline-dependent trans-activators. Hum Gene Ther 2002;13:199-210.
18. Lai JF, Cheng HY, Cheng TL, et al. Doxycycline- and tetracycline- regulated transcriptional silencer enhance the expression level and trans-activating performance of rtTA. J Gene Med 2004;6:1403-13.
19. Urlinger S, Baron U, Thellmann M, Hasan MT, Bujard H, Hillen W. Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. Proc Natl Acad Sci U S A 2000;97:7963-8.
20. Barde I, Zanta-Boussif MA, Paisant S, et al. Efficient control of gene expression in the hematopoietic system using a single Tet-On inducible lentiviral vector. Mol Ther 2006;13:382-90.
21. Bornkamm GW, Berens C, Kuklik-Roos C, et al. Stringent doxycycline-dependent control of gene activities using an episomal one-vector system. Nucleic Acids Res 2005;33:e137.
22. Fechner H, Wang X, Pico AH, et al. A bidirectional Tet-dependent promotor construct regulating the expression of E1A for tight control of oncolytic adenovirus replication. J Biotechnol 2007;127:560-74.
23. Sipo I, Hurtado Pico A, Wang X, et al. An improved Tet-On regulatable FasL-adenovirus vector system for lung cancer therapy. J Mol Med 2006;84:215-25.
24. Freundlieb S, Schirra-Muller C, Bujard H. A tetracycline controlled activation/repression system with increased potential for gene transfer into mammalian cells. J Gene Med 1999;1:4-12.
25. Salucci V, Scarito A, Aurisicchio L, et al. Tight control of gene expression by a helper-dependent adenovirus vector carrying the rtTA2(s)-M2 tetracycline transactivator and repressor system. Gene Ther 2002;9:1415-21.
26. Lamartina S, Silvi L, Roscilli G, et al. Construction of an rtTA2(s)-m2/tts(kid)-based transcription regulatory switch that displays no basal activity, good inducibility, and high responsiveness to doxycycline in mice and non-human primates. Mol Ther 2003;7:271-80.
27. Lena AM, Giannetti P, Sporeno E, Ciliberto G, Savino R. Immune responses against tetracycline-dependent transactivators affect long-term expression of mouse erythropoietin delivered by a helper-dependent adenoviral vector. J Gene Med 2005;7:1086-96.
28. de la Chapelle A. Genetic predisposition to colorectal cancer. Nat Rev Cancer 2004;4:769-80.
29. Alemany R, Gomez-Manzano C, Balague C, et al. Gene therapy for gliomas: molecular targets, adenoviral vectors, and oncolytic adenoviruses. Exp Cell Res 1999;252:1-12.
30. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21:137-48.
31. Berkenblit A, Matulonis UA, Kroener JF, et al. A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial. Gynecol Oncol 2005;99:50-7.
32. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006;24:769-77.
33. Vredenburgh JJ, Desjardins A, Herndon JE II, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13:1253-9.
34. Kunwar S, Prados MD, Chang SM, et al. Direct intracerebral delivery of cintredekin besudotox (IL13-38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 2007;25:837-44.
35. Puri RK, Leland P, Obiri NI, et al. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR). Blood 1996;87:4333-9.
36. Debinski W, Gibo DM, Obiri NI, Kealiher A, Puri RK. Novel anti-brain tumor cytotoxins specific for cancer cells. Nat Biotechnol 1998;16:449-53.
37. Gondi CS, Lakka SS, Yanamandra N, et al. Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis. Oncogene 2003;22:5967-75.
38. Watanabe M, Nasu Y, Kashiwakura Y, et al. Adeno-associated virus 2-mediated intratumoral prostate cancer gene therapy: long-term maspin expression efficiently suppresses tumor growth. Hum Gene Ther 2005;16:699-710.
39. Takei Y, Mizukami H, Saga Y, et al. Suppression of ovarian cancer by muscle-mediated expression of soluble VEGFR-1/Flt-1 using adeno-associated virus serotype 1-derived vector. Int J Cancer 2007;120:278-84.
40. Chiocca EA, Abbed KM, Tatter S, et al. A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 2004;10:958-66.
41. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-62.
42. Kawakami K, Kawakami M, Kioi M, Husain SR, Puri RK. Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model. J Neurosurg 2004;101:1004-11.
43. Bevan P, Mala C, Buergle M, Schmalix W, Neville N. A phase I pharmacokinetic (PK) study of single dose oral therapy with a uPA inhibitor (WX-671). J Clin Oncol 2006;24:13091.
44. Robinson SN, Chavez JM, Pisarev VM, et al. Delivery of Flt3 ligand (Flt3L) using a poloxamer-based formulation increases biological activity in mice. Bone Marrow Transplant 2003;31:361-9.
45. Marini G, Forno G, Kratje R, Etcheverrigaray M. Recombinant human granulocyte-macrophage colony-stimulating factor: effect of glycosylation on pharmacokinetic parameters. Electronic J Biotechnol 2007;10:271-8.
46. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200-5.
47. Bible KC, Lensing JL, Nelson SA, et al. Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. Clin Cancer Res 2005;11:5935-41.
48. Curtin JF, King GD, Candolfi M, et al. Combining cytotoxic and immune-mediated gene therapy to treat brain tumors. Curr Top Med Chem 2005;5:1151-70.
49. Senzer N, Mani S, Rosemurgy A, et al. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor a gene: a phase I study in patients with solid tumors. J Clin Oncol 2004;22:592-601.
50. Michieli P, Mazzone M, Basilico C, et al. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 2004;6:61-73.
51. Tolcher AW, Hao D, de Bono J, et al. Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer. J Clin Oncol 2006;24:2052-8.
52. Alonso MM, Gomez-Manzano C, Jiang H, et al. Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect in vivo. Cancer Gene Ther 2007;14:756-61.
53. Pulkkanen KJ, Yla-Herttuala S. Gene therapy for malignant glioma: current clinical status. Mol Ther 2005;12:585-98.